The vice president of this pharmaceutical company has been replaced! The company's net profit in the first half of the year increased by 20% year-on-year

【Pharmaceutical Network Enterprise News】On August 30, TusPark issued an announcement that the company's board of directors recently received a written resignation report
submitted by Mr.
Liu Bingcheng, vice president of the company.

Mr.
Liu Bingcheng applied to resign as Vice President due to work adjustment reasons, and after his resignation, Mr.
Liu Bingcheng still held other positions in the
Company.

As at the date of this announcement, Mr.
Liu Bingcheng does not hold shares in the Company and has no commitments
that should be fulfilled but have not been fulfilled.

On the same day, TusPark Pharmaceutical announced that in order to meet the needs of the company's operation and management, after the nomination of Mr.
Feng Xue, the president of the company, and the review of the nomination committee of the board of directors, the board of directors of the company agreed to appoint Mr.
Wen Ge as the vice president of the company, and the term of office was from the date of deliberation and approval of the board of directors to the date of expiration of the term of the ninth board of directors
.

According to the resume, Mr.
Wen Ge has successively served as the first deputy director of the pill workshop of Hengyang Chinese Medicine Factory, the director of the oral liquid workshop, the director of the factory office, the secretary of the Discipline Inspection Commission, the supervisor, the secretary of the Discipline Inspection Committee, the chairman of the trade union, the deputy general manager, the secretary of the board of directors and the executive deputy general manager of Hengyang Chinese Medicine Co.
, Ltd.
of Tsinghua Guhan Group, and the secretary and general manager of the board of directors of Hengyang Chinese Medicine Co.
, Ltd.
of Tuspark Guhan Group; He is currently the Senior Vice President of TusPark and the Executive Director and General Manager
of Guhan Chinese Medicine Co.
, Ltd.

TusPark pharmaceuticals is located in the pharmaceutical manufacturing industry
.

The company is mainly committed to the research and development of traditional Chinese medicine secret recipes, prescriptions and Western medicine preparations, the production of ancient Han health essence (oral liquid, tablets), heart palpitation granules, kidney and waist pills and other proprietary Chinese medicines and large-volume injections, APIs, five-dimensional lysine oral solution and other Western medicine preparations
.

The main products and services are widely used in various fields
of treatment as well as healthcare.

According to the 2022 semi-annual report, tusS Pharmaceutical's operating income in the first half of the year was about 178 million yuan, an increase of 20.
12% year-on-year; Net profit attributable to shareholders of listed companies was about 11.
55 million yuan, a year-on-year decrease of 60.
43%; Basic earnings per share were RMB0.
0482, down 60.
46%
year-on-year.

It is proposed not to distribute cash, not to send bonus shares, and not to increase
.

It is reported that the main reason for the decline in the company's net profit in the first half of the year was the increase in the price of raw materials for major products, resulting in an increase in costs and a year-on-year decline in gross profit margin; And in order to expand the sales market, the company increased its marketing efforts, resulting in an increase
in sales expenses year-on-year.

During the reporting period, the production and sales of traditional Chinese medicines and health care products accounted for 83.
24% of the company's operating income, the production and sales of Western medicines accounted for 3.
01% of the revenue, and the others accounted for 13.
74%.
It is worth mentioning that the core products produced by the company are guhan health essence, the proportion of series products in production and sales is high, the product structure is relatively single, and it is still limited by sales in the province; With the continuous deepening of the reform of the national medical system, the new version of the national medical insurance catalogue restricts the use of many drugs, and many places have successively introduced auxiliary drug supervision catalogues, which are greatly affected by pharmaceutical industry policies, market fluctuations and factors such as the company's product sales and quality, and the risk concentration is high
.

In this regard, TusPark Pharmaceutical said that it will continue to maintain the stability and growth of the Guhan health care essence market in Hunan Province, increase market investment and expansion outside the province, and strictly supervise product quality; At the same time, we continue to increase investment in research and development, look for products with high clinical value and low economic cost, and through research and development and mergers and acquisitions, we will continue to enrich the product line to obtain more new products, adjust and optimize the product structure, disperse the risks that a single product may bring, and at the same time accelerate the extension of the company's industrial chain and lay out the big health medicine and health care industry
.

According to the semi-annual report, TusPark invested 5.
3303 million yuan in research and development in the first half of the year, an increase of 41.
72%
over the same period of the previous year of 3.
7612 million yuan.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.